Update in Cardiovascular Drug Therapy: Antiplatelet Therapy for Atherosclerotic Disease

Consultant Pharmacist

Volumn 18, Issue SUPPL. C, 2003, Pages 4-9

  Bottorff, Michael B ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antiplatelet drugs; Arterial atherothrombosis; Aspirin; Clopidogrel; Platelet; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR; RECOMBINANT PLASMINOGEN ACTIVATOR; STAPHYLOKINASE; TENECTEPLASE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPOTENSION; PRURITUS; RASH; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0842321065     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. American Heart Association. 1998 Heart Disease and Stroke Statistical Update. Dallas, Texas: American Heart Association; 1997.
2. National Heart, Lung, and Blood Institute. NHLBI Morbidity and Mortality Chartbook, 1996. Bethesda, Maryland,: National Institutes of Health.
3. Criqui MH, Fronek A, Barrett-Conner E et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.
4. Dormandy JA, Murray GD. The fate of the claudicant - a prospective study of 1969 claudicants. Eur J Vasc Surg 1991;5:131-3.
5. Libby P. Mechanisms of thrombosis in acute coronary syndromes [videotape]. Boston, Massachusetts: 2002
6. Schafer AI. Antiplatelet therapy. Am J Med 1996;101:199-209.
7. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;14(suppl):470S-488S.
8. Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
9. Helgason CM, Tortorice KL, Winkler SR et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-50.
10. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
11. Mueller MR, Salat A, Stangl P et al. Variable platelet response to a low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
12. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348: 1329-39.
13. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000;36: 970-1062.
14. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoproteins IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999;34:1395-402.
15. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.